Atopic Dermatitis

Researchers report that atopic dermatitis (AD) is associated with increased risk of ADHD in adults and children. Patients with more severe AD were at even higher risk.

The aspects of atopic dermatitis that most concern patients and their caregivers are not well represented among the areas that are studied in clinical research.

A modified Goeckerman regimen was associated with significant improvement of symptoms in patients with chronic, severe atopic dermatitis.

The two major causes of atopic dermatitis: dysfunctional dermal barrier and immune responses.

Proactive administration of topical corticosteroid was found to reduce allergen sensitization in patients with atopic dermatitis (AD) as well as the periodic exacerbation of pruritic eczema.

Approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease, ustekinumab appeared to benefit patients with severe atopic dermatitis (AD) in a small study seeking to correlate its immunologic effects with clinical efficacy.

A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.

Atopic dermatitis comes with added infection risk.

Eric Simpson, MD, the lead author on the study, spoke to MD Magazine about the results, which showed great improvement with few side effects for those with moderate or severe atopic dermatitis.

Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.

Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.

The issue of when to use eczema and when atopic dermatitis has thrown a wrench into data-mining machinations.

Childhood atopic dermatitis (AD) usually resolves before adulthood, a meta-analysis of cases showed. Those patients who did see their AD persist were more likely to be female, to have been older at onset, and to have relatively severe AD.

An early clinical trial of a topical preparation of tofacitinib, a janus kinase (JAK) inhibitor, demonstrated that it improved symptoms of atopic dermatitis (AD) and was well tolerated.

A disease that was much-feared but now so rare it is often mistaken for atopic dermatitis, leprosy has been confirmed in a California elementary school pupil. Armadillos are known to harbor and spread the bacteria that cause it.

The drug, a fully human monoclonal antibody that has impressed equally in asthma and atopic dermatitis trials, may be approved for market as soon as March of 2017.

Across the board, researchers saw that studies of active smokers showed increased prevalence of the skin condition, regardless of age or region. It isn't quite clear, though, whether smoking causes AD or AD causes people to smoke.

An increasing number of studies of treatment effectiveness for atopic dermatitis (AD) are measuring changes in quality of life (QOL) as well as in symptoms.

Topical corticosteroid worked as well as bleach in transforming the microbiota of affected skin to that of healthy skin, an NYU study found.

Phototherapy can be effective in treating AD but not all patients have access to the therapy, a study found.

Are people with atopic dermatitis at a higher or lower risk of developing skin cancer? Researchers found conflicting evidence.

In the past 15 years, no new topical AD treatments have been approved. Crisaborole, however, could be an efficient, safe, non-steoidal treatment option, according to the results of two recent phase III studies.

As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.

An experimental inpatient program worked for atopic dermatitis that had not been resolved despite treatment.

French investigators did a retrospective study of atopic dermatitis treatment and found immunosuppressive agents were well tolerated and worked.

The antifungal, sertaconazole (Ertaczo, Valeant, others), was no better than the topical vehicle placebo in a well controlled, multicenter trial to treat unremitting pruritus in atopic dermatitis (AD).

As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.

Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.

As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.